Bent Laursen Ejlertsen

Research output

Research output per year 1994 2008 2009 2013 2019

• 36 Journal article
• 1 Review

Research output per year

Research output per year

Search results

• 2019

  Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer

  Sønderstrup, I. M. H., Jensen, M. B., Ejlertsen, B., Eriksen, J. O., Gerdes, A. M., Kruse, T. A., Larsen, M. J., Thomassen, M. & Lænkholm, A. V., 4 Mar 2019, In: Acta Oncologica. 58, 3, p. 363-370 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Breast Neoplasms 50%
  • Mutation 11%
  • Germ-Line Mutation 7%
  • Survival 7%
  8 Citations (Scopus)

• Heavy-load resistance exercise during chemotherapy in physically inactive breast cancer survivors at risk for lymphedema: a randomized trial

  Bloomquist, K., Adamsen, L., Hayes, S. C., Lillelund, C., Andersen, C., Christensen, K. B., Oturai, P., Ejlertsen, B., Tuxen, M. K. & Møller, T., 2 Dec 2019, In: Acta Oncologica.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Lymphedema 100%
  • Cancer Survivors 91%
  • Exercise 54%
  • Breast Neoplasms 53%
  • Drug Therapy 49%
  7 Citations (Scopus)

• Overcoming Treatment Toxicity through Sequential Therapy

  Benada, J., Ejlertsen, B. & Sørensen, C. S., 10 Jun 2019, In: Cancer Cell. 35, 6, p. 821-822 2 p.

  Research output: Contribution to journal › Journal article › Research

  • DNA Damage 100%
  • Neoplasms 37%
  • Therapeutics 18%
  1 Citation (Scopus)

• Whole genome sequencing of breast cancer

  Rossing, M., Sørensen, C. S., Ejlertsen, B. & Nielsen, F. C., May 2019, In: APMIS - Journal of Pathology, Microbiology and Immunology. 127, 5, p. 303-315 13 p.

  Research output: Contribution to journal › Review › peer-review

  • Whole Genome Sequencing 100%
  • Breast Neoplasms 54%
  • Familial Breast Cancer 24%
  • Precision Medicine 18%
  • Genetic Association Studies 18%
  6 Citations (Scopus)

  18 Downloads (Pure)
• 2018

  Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial

  Banke, A., Fosbøl, E. L., Møller, J. E., Gislason, G. H., Andersen, M., Bernsdorf, M., Jensen, M. B., Schou, M. & Ejlertsen, B., 2018, In: European Journal of Heart Failure. 20, 10, p. 1447-1453 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Epirubicin 100%
  • Heart Failure 57%
  • Randomized Controlled Trials 53%
  • Breast Neoplasms 50%
  • Incidence 38%
  24 Citations (Scopus)
• 2016

  A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: study protocol

  Bloomquist, K., Hayes, S., Adamsen, L., Møller, T., Christensen, K. B., Ejlertsen, B. & Oturai, P., 22 Jul 2016, In: B M C Cancer. 16, 8 p., 517.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Lymphedema 100%
  • Adjuvant Chemotherapy 84%
  • Cross-Over Studies 75%
  • Arm 73%
  • Exercise 54%
  7 Citations (Scopus)

  133 Downloads (Pure)
• 2015

  Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

  Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D. F., Antoniou, A. C., Nathanson, K. L., Laitman, Y., Kushnir, A., Paluch-Shimon, S., Berger, R., Zidan, J., Friedman, E., Ehrencrona, H., Stenmark-Askmalm, M., Einbeigi, Z., & 31 othersLoman, N., Harbst, K., Rantala, J., Melin, B., Huo, D., Olopade, O. I., Seldon, J., Ganz, P. A., Nussbaum, R. L., Chan, S. B., Odunsi, K., Gayther, S. A., Domchek, S. M., Arun, B. K., Lu, K. H., Mitchell, G., Karlan, B. Y., Walsh, C., Lester, J., Godwin, A. K., Pathak, H., Ross, E., Daly, M. B., Whittemore, A. S., John, E. M., Miron, A., Terry, M. B., Chung, W. K., Ejlertsen, B., Gerdes, A-M. & CIMBA Consortium, 7 Apr 2015, In: J A M A: The Journal of the American Medical Association. 313, 13, p. 1347-61 15 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Ovarian Neoplasms 100%
  • Breast Neoplasms 70%
  • Mutation 61%
  • Neoplasms 14%
  • Breast Cancer 3 13%
  245 Citations (Scopus)

• Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study

  Tvedskov, T. F., Jensen, M-B., Ejlertsen, B., Christiansen, P., Balslev, E. & Kroman, N., 3 Oct 2015, In: Breast Cancer Research and Treatment. 153, 3, p. 599-606 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Neoplasm Micrometastasis 100%
  • Dissection 67%
  • Lymph Node Excision 51%
  • Breast Neoplasms 50%
  • Recurrence 26%
  11 Citations (Scopus)

• The challenge of preserving cardiorespiratory fitness in physically inactive patients with colon or breast cancer during adjuvant chemotherapy: A randomised feasibility study

  Møller, T., Lillelund, C., Andersen, C., Bloomquist, K., Christensen, K. B., Ejlertsen, B., Nørgaard, L., Wiedenbein, L., Oturai, P., Breitenstein, U. & Adamsen, L., 2015, In: BMJ Open Sport and Exercise Medicine. 1, 14 p., e000021.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Cardiorespiratory Fitness 100%
  • Feasibility Studies 80%
  • Adjuvant Chemotherapy 78%
  • Colonic Neoplasms 69%
  • Breast Neoplasms 49%
  14 Citations (Scopus)
• 2014

  TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group

  Jørgensen, C. L. T., Bjerre, C. A., Ejlertsen, B. L., Bjerre, K. D., Balslev, E., Bartels, A., Brünner, N. & Nielsen, D. L., 22 May 2014, In: B M C Cancer. 14, 14 p., 360.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tissue Inhibitor of Metalloproteinase-1 100%
  • gemcitabine 93%
  • Breast Neoplasms 53%
  • Docetaxel 43%
  • Survival 13%
  6 Citations (Scopus)

  784 Downloads (Pure)
• 2013

  At cancer diagnosis: a 'window of opportunity' for behavioural change towards physical activity. A randomised feasibility study in patients with colon and breast cancer

  Møller, T., Lillelund, H. C. D., Andersen, C., Ejlertsen, B., Nørgaard, L., Christensen, K. B., Vadstrup, E., Diderichsen, F., Hendriksen, C., Bloomquist, K. & Adamsen, L., 2013, In: B M J Open. 3, 11, e003556.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Feasibility Studies 100%
  • Colonic Neoplasms 86%
  • Exercise 62%
  • Breast Neoplasms 61%
  • Adjuvant Chemotherapy 58%
  20 Citations (Scopus)

• Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling

  Larsen, M. J., Kruse, T. A., Tan, Q., Lænkholm, A-V., Bak, M., Lykkesfeldt, A. E., Sørensen, K. P., Hansen, T. V. O., Ejlertsen, B., Gerdes, A-M. & Thomassen, M., 21 May 2013, In: P L o S One. 8, 5, 12 p., e64268.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Profiling 100%
  • RNA 85%
  • Tumor 75%
  • tumor 74%
  • Tumors 72%
  59 Citations (Scopus)

• Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark

  Anderson, W. F., Rosenberg, P. S., Petito, L., Katki, H. A., Ejlertsen, B., Ewertz, M., Rasmussen, B. B., Jensen, M-B. & Kroman, N., Nov 2013, In: International journal of cancer. Journal international du cancer. 133, 9, p. 2201–2206 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • estrogens 100%
  • Denmark 90%
  • breast 62%
  • cancer 55%
  • Estrogen Receptors 55%
  28 Citations (Scopus)

• Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

  Jørgensen, C. L., Ejlertsen, B., Bjerre, K. D., Balslev, E., Nielsen, D. L. & Nielsen, K. V., 12 Nov 2013, In: B M C Cancer. 13, p. 1-11 11 p., 541.

  Research output: Contribution to journal › Journal article › Research › peer-review

  10 Citations (Scopus)

• One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer

  Ejlertsen, B., Jensen, M-B., Elversang, J., Rasmussen, B. B., Andersson, M., Andersen, J., Nielsen, D. L., Cold, S. & Mouridsen, H. T., Sept 2013, In: European journal of cancer (Oxford, England : 1990). 49, 14, p. 2986-2994 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tamoxifen 100%
  • Methotrexate 78%
  • Fluorouracil 77%
  • Cyclophosphamide 75%
  • Breast Neoplasms 60%
  6 Citations (Scopus)

• The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue

  Andersen, C., Rørth, M., Ejlertsen, B., Stage, M., Møller, T., Midtgaard, J., Quist, M., Bloomquist, K. & Adamsen, L., Jun 2013, In: European Journal of Oncology Nursing. 17, 3, p. 331-339 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  57 Citations (Scopus)
• 2012

  TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients

  Hertel, P. B., Tu, D., Ejlertsen, B. L., Jensen, M-B. R., Balslev, E., Jiang, S., O'Malley, F. P., Pritchard, K. I., Shepherd, L. E., Bartels, A., Brunner, N. & Nielsen, T. O., Feb 2012, In: Breast Cancer Research and Treatment. 132, 1, p. 225-234 10 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tissue Inhibitor of Metalloproteinase-1 100%
  • Anthracyclines 95%
  • Fluorouracil 79%
  • Cyclophosphamide 77%
  • Breast Neoplasms 53%
  11 Citations (Scopus)
• 2011

  Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

  Ramus, S. J., Kartsonaki, C., Gayther, S. A., Pharoah, P. D. P., Sinilnikova, O. M., Beesley, J., Chen, X., McGuffog, L., Healey, S., Couch, F. J., Wang, X., Fredericksen, Z., Peterlongo, P., Manoukian, S., Peissel, B., Zaffaroni, D., Roversi, G., Barile, M., Viel, A., Allavena, A., & 31 othersOttini, L., Papi, L., Gismondi, V., Capra, F., Radice, P., Greene, M. H., Mai, P. L., Andrulis, I. L., Glendon, G., Ozcelik, H., Thomassen, M., Gerdes, A-M., Kruse, T. A., Cruger, D., Jensen, U. B., Caligo, M. A., Olsson, H., Kristoffersson, U., Lindblom, A., Arver, B., Karlsson, P. W., Stenmark Askmalm, M., Borg, A., Neuhausen, S. L., Ding, Y. C., Nathanson, K. L., Domchek, S. M., Hansen, T. V. O., Jønson, L., Ejlertsen, B. & OCGN, 19 Jan 2011, In: National Cancer Institute. Journal (Print). 103, 2, p. 105-16 12 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Genetic Variation 100%
  • Ovarian Neoplasms 94%
  • Mutation 57%
  • Single Nucleotide Polymorphism 34%
  • Alleles 30%
  34 Citations (Scopus)
• 2010

  Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer

  Hansen, T. V. O., Jønson, L., Albrechtsen, A., Steffensen, A. Y., Bergsten, E. B., Myrhøj, T., Ejlertsen, B. L. & Nielsen, F. C., Nov 2010, In: Breast Cancer Research and Treatment. 124, 1, p. 259-264 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Inuits 100%
  • Genetic Testing 69%
  • Ovarian Neoplasms 61%
  • Nucleotides 54%
  • Breast Neoplasms 42%
  7 Citations (Scopus)
• 2009

  A common Greenlandic Inuit BRCA1 RING domain founder mutation

  Hansen, T. V. O., Ejlertsen, B., Albrechtsen, A., Bergsten, E., Bjerregaard, P., Hansen, T., Myrhoj, T., Nielsen, P. B., Timmermans-Wielenga, V., Andersen, M. K., Jonson, L. & Nielsen, F. C., 2009, In: Breast Cancer Research and Treatment. 115, 1, p. 69-76 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  16 Citations (Scopus)

• A high frequent BRCA1 founder mutation identified in the Greenlandic population

  Harboe, T. L., Eiberg, H., Kern, P., Ejlertsen, B., Nedergaard, L., Timmermans-Wielenga, V., Nielsen, I-M. & Bisgaard, M. L., 2009, In: Familial Cancer. 8, 4, p. 413-9 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Mutation 100%
  • Population 69%
  • Ovarian Neoplasms 50%
  • Breast Neoplasms 43%
  • Greenland 41%
  17 Citations (Scopus)

• An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer

  Henriksen, K. L., Rasmussen, B. B., Lykkesfeldt, A. E., Møller, S., Ejlertsen, B. & Mouridsen, H. T., 2009, In: Acta Odontologica Scandinavica. 48, 4, p. 522-31 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Letrozole 100%
  • Tamoxifen 76%
  • Progesterone Receptors 76%
  • Estrogen Receptors 67%
  • Patient Selection 63%
  23 Citations (Scopus)

• In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer

  Lykkesfeldt, A. E., Henriksen, K. L., Rasmussen, B. B., Sasano, H., Evans, D. B., Møller, S., Ejlertsen, B. & Mouridsen, H. T., 2009, In: BMC Cancer. 9, p. 185

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Aromatase 100%
  • Estrogen Receptors 76%
  • Breast Neoplasms 51%
  • Progesterone Receptors 28%
  • Estrogens 26%
  13 Citations (Scopus)

• Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer: A Danish Breast Cancer Cooperative Group Study

  Willemoe, G. L., Hertel, P. B., Bartels, A., Jensen, M-B., Balslev, E., Rasmussen, B. B., Mouridsen, H. T., Ejlertsen, B. L. & Brunner, N., 2009, In: European Journal of Cancer. 45, 14, p. 2528-2536 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  27 Citations (Scopus)

• Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families

  Hansen, T. V. O., Jønson, L., Albrechtsen, A., Andersen, M. K., Ejlertsen, B. & Nielsen, F. C., May 2009, In: Breast Cancer Research and Treatment. 115, 2, p. 315-323 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Ovarian Neoplasms 100%
  • Exons 91%
  • Breast Neoplasms 70%
  • Mutation 27%
  • Chromosomes, Human, Pair 17 15%
  46 Citations (Scopus)

• Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer

  Ejlertsen, B., Jensen, M-B., Rank, F., Rasmussen, B. B., Christiansen, P., Kroman, N., Kvistgaard, M. E., Overgaard, M., Toftdahl, D. B., Mouridsen, H. T. & Danish Breast Cancer Cooperative Group, 2009, In: JNCI - Journal of the National Cancer Institute. 101, 10, p. 729-35 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Population 61%
  • Confidence Intervals 43%
  • Survival 13%
  • Kaplan-Meier Estimate 12%
  68 Citations (Scopus)

• The silent mutation nucleotide 744 G --> A, Lys172Lys, in exon 6 of BRCA2 results in exon skipping

  Hansen, T. V. O., Steffensen, A. Y., Jønson, L., Andersen, M. K., Ejlertsen, B. & Nielsen, F. C., 2009, In: Breast Cancer Research and Treatment. 119, 3, p. 547-50 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Silent Mutation 100%
  • Exons 60%
  • Nucleotides 58%
  • Ovarian Neoplasms 33%
  • Mutation 30%
  20 Citations (Scopus)
• 2008

  [Preoperative chemotherapy in operable breast cancer. A survey of a Cochrane review]

  Petersen, M. B. & Ejlertsen, B., 2008, In: Ugeskrift for læger. 170, 39, p. 3048-3050 2 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

• Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89

  Ejlertsen, B., Mouridsen, H. T. & Jensen, M. B., 2008, In: Acta Oncologica. 47, 4, p. 662-671 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  12 Citations (Scopus)

• Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

  Kristensen, B., Ejlertsen, B., Mouridsen, H. T., Jensen, M. B., Andersen, J., Bjerregaard, B., Cold, S., Edlund, P., Ewertz, M., Kamby, C., Lindman, H., Nordenskjold, B. & Bergh, J., 2008, In: Acta Oncologica. 47, 4, p. 740-746 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  67 Citations (Scopus)

• DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients

  Ejlertsen, B., Jensen, M. B., Mouridsen, H. T., Andersen, J., Cold, S., Jakobsen, E., Kamby, C., Sørensen, P. & Ewertz, M., 2008, In: Acta Oncologica. 47, 4, p. 709-717 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  5 Citations (Scopus)

• Pregnancy after treatment of breast cancer--a population-based study on behalf of Danish Breast Cancer Cooperative Group

  Kroman, N., Jensen, M. B., Wohlfahrt, J. & Ejlertsen, B., 2008, In: Acta Oncologica. 47, 4, p. 545-549 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  97 Citations (Scopus)

• Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

  Andersen, J., Kamby, C., Ejlertsen, B., Cold, S., Ewertz, M., Jacobsen, E. H., Philip, P., Møller, K. A., Jensen, D. & Møller, S., 2008, In: Acta Oncologica. 47, 4, p. 718-724 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  16 Citations (Scopus)

• The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

  Moller, S., Jensen, M. B., Ejlertsen, B., Bjerre, K. D., Larsen, M., Hansen, H. B., Christiansen, P. & Mouridsen, H. T., 2008, In: Acta Oncologica. 47, 4, p. 506-524 18 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  215 Citations (Scopus)

• The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D

  Nielsen, K. V., Ejlertsen, B., Moller, S., Jørgensen, J. T., Knoop, A., Knudsen, H. & Mouridsen, H. T., 2008, In: Acta Oncologica. 47, 4, p. 725-734 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  88 Citations (Scopus)

• Vinorelbine as first-line or second-line therapy for advanced breast cancer: a Phase I-II trial by the Danish Breast Cancer Co-operative Group

  Langkjer, S. T., Ejlertsen, B., Mouridsen, H., Andersen, J., Nielsen, M. M., Moller, K. A., Madsen, E. L. & Haarh, V., 2008, In: Acta Oncologica. 47, 4, p. 735-739 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  13 Citations (Scopus)
• 1994

  Tanoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study.

  Kristensen, B., Ejlertsen, B. L., Dalgaard, P., Larsen, L., Holmegaard, S. N., Transbøl, I. & Mouridsen, H. T., 1994, In: Journal of Clinical Oncology. 12, p. 992-997

  Research output: Contribution to journal › Journal article › Research › peer-review

  188 Citations (Scopus)